Medication-related problem type and appearance rate in ambulatory hemodialysis patients
Open Access
- 22 December 2003
- journal article
- research article
- Published by Springer Nature in BMC Nephrology
- Vol. 4 (1) , 10
Abstract
Hemodialysis (HD) patients are at risk for medication-related problems (MRP). The MRP number, type, and appearance rate over time in ambulatory HD patients has not been investigated. Randomly selected HD patients were enrolled to receive monthly pharmaceutical care visits. At each visit, MRP were identified through review of the patient chart, electronic medical record, patient interview, and communications with other healthcare disciplines. All MRP were categorized by type and medication class. MRP appearance rate was determined as the number of MRP identified per month/number of months in study. The number of MRP per patient-drug exposures were determined using: {[(number of patients) × (mean number of medications)]/(number of months of study)} /number of MRP identified. Results were expressed as mean ± standard deviation or percentages. Patients were 62.6 ± 15.9 years old, had 6.4 ± 2.0 comorbid conditions, were taking 12.5 ± 4.2 medications, and 15.7 ± 7.2 doses per day at baseline. Medication-dosing problems (33.5%), adverse drug reactions (20.7%), and an indication that was not currently being treated (13.5%) were the most common MRP. 5,373 medication orders were reviewed and a MRP was identified every 15.2 medication exposures. Overall MRP appearance rate was 0.68 ± 0.46 per patient per month. MRP continue to occur at a high rate in ambulatory HD patients. Healthcare providers taking care of HD patients should be aware of this problem and efforts to avoid or resolve MRP should be undertaken at all HD clinics.Keywords
This publication has 20 references indexed in Scilit:
- Adverse Drug Events in Ambulatory CareNew England Journal of Medicine, 2003
- Factors associated with medication-related problems in ambulatory hemodialysis patientsAmerican Journal of Kidney Diseases, 2003
- Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney diseaseAmerican Heart Journal, 2002
- The Clinical and Economic Impact of Pharmaceutical Care in End‐Stage Renal Disease PatientsSeminars in Dialysis, 2002
- Drug-Related Deaths in a Department of Internal MedicineArchives of internal medicine (1960), 2001
- Drug-Related Morbidity and Mortality: Updating the Cost-of-Illness ModelJournal of the American Pharmaceutical Association, 2001
- Comparing medication use in two hemodialysis units against national dialysis databasesAmerican Journal of Health-System Pharmacy, 2000
- Reduction in Heart Failure Events by the Addition of a Clinical Pharmacist to the Heart Failure Management TeamArchives of internal medicine (1960), 1999
- Pharmacist Participation on Physician Rounds and Adverse Drug Events in the Intensive Care UnitJAMA, 1999
- Incidence of Adverse Drug Reactions in Hospitalized PatientsJAMA, 1998